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This paper presents a critical evaluation of the use of systemic antimi-
crobial treatment in periodontal disease. Recognizing specific types of
periodontal infections can significantly influence the choice of antimicro-
bial treatment. Therapy should be tailored to differences in antibiotic
susceptibility between various periodontal pathogens.
Many different antibiotic regimens have been described in the liter-
ature, making the choice in clinical practice difficult. Numerous stud-
ies have examined the impact of systemic antibiotic treatment in stop-
ping the progression of periodontal diseases. Major candidates for
antibiotic therapy are patients whose disease continues to progress
despite conventional mechanical treatment. Antibiotics can also be used
in patients with localized aggressive or other early developed forms of
periodontitis, as well as in patients with systemic diseases affecting
the course of periodontitis. They have proven to be beneficial as an
adjunct to standard therapy. Serious side-effects of systemic antibiotic
treatment, such as development of resistance and increase in opportunis-
tic microorganisms, do not justify their use in the treatment of chron-
ic, slowly-progressive forms of periodontal diseases.
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Introduction
Gingivitis and periodontitis are the two most
common infectious periodontal diseases. Gingivi-
tis occurs in almost all individuals. Advanced peri-
odontitis is found in 10-20 % of the adult popula-
tion. Both diseases are primarily caused by supra-
and subgingival microbial plaque, possessing the
properties of a biofilm. Microbial composition of
pathogenic plaque has been studied over the last two
to three decades. A higher percentage of certain
microbial species in the subgingival plaque has been
related to active destructive periodontal disease.
Some of the periodontally pathogenic bacteria are:
Actinobacillus actinomycetemcomitans, Porphyro-
monas gingivalis, Prevotella intermedia, Bacteroi-
des forsythus, Peptostreptococcus micros, Campy-
lobacter rectus, Eikenella corrodens, Fusobacteri-
um nucleatum, Treponema denticola, certain Enter-
obacteriaceae species and staphylococci (1-3).
Elimination or adequate suppression of periodon-
tal pathogens in the subgingival microflora is essen-
tial for periodontal healing to take place. Antimicro-
bial therapy in periodontology includes mechani-
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cal debridement of the root surfaces, oral hygiene
measures and local and systemic antimicrobial
chemotherapy.
Inflammatory periodontal diseases are primari-
ly treated with supra- and subgingival scaling of the
affected tooth surfaces. Clinical improvement is
directly related to the reduction or removal of the
subgingival pathogenic plaque (4-6). The majority
of subgingival bacteria is sensitive to the antimi-
crobial effect of mechanical therapy (7). Mechani-
cal and surgical treatment, combined with proper
oral hygiene, in most cases arrests further periodon-
tal attachment loss. However, despite well performed
mechanical treatment, in some individuals the clin-
ical attachment destruction cannot be stopped.
Refractory periodontitis and diminished immune
host response (8) can be related to residual subgin-
gival pathogens (9, 10). Numerous studies have
shown that mechanical debridement cannot effec-
tively eliminate A. actinomycetemcomitans, P. gin-
givalis, P. intermedia, B. forsythus, P. micros, enter-
obacteria and some other bacterial species (5, 6, 11,
12-14). The reason is the ability of the mentioned
bacterial species to invade gingival epithelial cells
and subepithelial connective tissue (15-18). Cer-
tain periodontal pathogens possess the ability to
recolonise the tooth surfaces from the tongue, ton-
sillae and buccal mucosa which act as reservoirs
(19). Targeted antimicrobial therapy could perhaps
suppress or eliminate residual periodontal pathogens,
and thus serve as an adjunct to conventional mechan-
ical therapy (20).
Microbial composition of subgingival plaque can
differ greatly between individual patients (21, 22).
Recent studies have shown that some subgingival
bacteria, including Actinobacillus actinomycetem-
comitans and Porphyromonas gingivalis, relatively
rarely occur in healthy periodontium, and are able
to stimulate production of specific antibodies in
patients with periodontitis. These bacteria are exoge-
nous microorganisms and could represent true peri-
odontal infections (23). Atypical (non-oral) patho-
genic enteric bacteria were isolated from some peri-
odontal lesions, and present superinfections. Peri-
odontal infections caused by oral microorganisms
can be considered endogenous periodontal infec-
tions. Knowing the type of periodontal infections
is important when choosing appropriate antimicro-
bial periodontal therapy (24). Antibiotic therapy of
severe periodontitis forms should be adapted to the
differential antimicrobial susceptibility of the peri-
odontal pathogens present (23, 25).
Microbiological analysis revealed that subjects
with the same clinical form of the disease have dif-
ferent bacterial composition of subgingival plaque,
and that the same bacteria can be found in different
clinical forms of the disease. Consequently, it is not
possible to relate specific bacteria to specific clini-
cal appearance, or discern between periodontitis
forms on the basis of microbiological isolates. This
conclusion is in accordance with modern under-
standing of periodontal disease as a result of the
interaction between microorganisms and different
host factors. The same microorganisms can lead to
different clinical forms of the disease (26).
Starting with the first investigations in the late
1970s, the use of antibiotics in periodontal therapy
has been controversial. The value of antibiotic ther-
apy has often been misinterpreted, overestimated or
over-simplified. In this article we will survey mod-
ern concepts of systemic antimicrobial therapy in
the treatment of periodontal diseases.
History
Microscopic studies at the beginning of the last
century revealed the presence of large numbers of
spirochetes and amoebas in subgingival plaque (27,
28). These microorganisms were held responsible
for the initiation of periodontal disease, and subse-
quently neo-salvarsan and ementin were used as
treatment. These anorganic arsenic drugs had very
dangerous side effects. After them appeared pron-
tosil, chemotherapeutic derived from artificial dyes,
one of its metabolites being sulfonamide. Sulfon-
amides are still being used in medicine. The begin-
ning of the antibiotic era was Flemming’s discov-
ery of Penicillium notatum mould producing a sub-
stance which inhibits Staphylococcus aureus growth.
Since then numerous antibiotics have been discov-
ered, which are used in medical or dental practice.
Although the advantages of antibiotic use in fight-
ing bacterial infection are huge, unwanted effects
such as resistance, toxicity, sensitivity and interac-
tion with other medications are often encountered.
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Traditionally, in periodontics antibiotics were
prescribed to patients not responding to conventional
mechanical treatment, or as an adjunct for peri-
odontal surgical procedures. Initially, the choice of
antibiotics was based on clinical experience and
mostly penicillins were used. Tetracycline hidrochlo-
ride became widely used during the 1970s, and the
advantages of its usage were its broad antimicrobial
spectrum and low systemic toxicity. First controlled
clinical studies testing the effectiveness of antibi-
otic therapy started in the late 1970s. Despite numer-
ous investigations, it is still not clear which is the
most effective antibiotic in periodontology. In the
literature, many different forms of antibiotic thera-
py have been described, making the choice of antibi-
otics very difficult.
The concept of antimicrobial therapy
The aim of antimicrobial therapy is to stop peri-
odontal attachment loss, and as far as possible, to
maintain the soft tissue esthetics. This includes
removal of bacterial plaque and calculus from the
root surfaces, surgical access if needed, and oral
hygiene instructions and removal of local plaque
retention factors.
Systemic antimicrobial therapy in periodontol-
ogy is based on the fact that specific bacterial species
cause periodontal destruction and that it is possible
to achieve bactericidal or bacteriostatic concentra-
tions of the antimicrobial substance in the peri-
odontal pocket (29). In comparison with mechani-
cal treatment or local delivery, systemically adminis-
tered antibiotics have several advantages. Through
serum it is possible to influence microorganisms
(Table 1) in the furcation area, or at the bottom of
a deep periodontal pocket, perhaps even bacteria
present in the epithelial or connective tissue of the
gingiva (30), or bacteria colonising oral mucosa or
extraoral locations (31, 32). Disadvantages of antibi-
otic therapy are possible adverse effects (Table 2)
(33, 34).
Since periodontal disease is not caused by one
microorganism, antibiotic usage for elimination of
one pathogenic species is not possible. In the best
case, antibiotics will suppress some subgingival bac-
teria over a limited period of time (35).
Most of the clinical studies only tested one
antibiotic, instead of comparing different kinds of
antibiotics. Therefore it is very difficult to give one-
sided, on scientific evidence-based recommendation
for the choice of antibiotic treatment of certain peri-
odontal clinical conditions (26).
Antibiotics in periodontal therapy
Tetracyclines
Tetracyclines are a group of broad-spectrum, bac-
teriostatic antibiotics. They are the first antimicro-
bial drugs which have been scientifically investi-
gated in periodontology. This group includes tetracy-
cline hydrochloride, minocycline and doxycycline.
In their double-blind clinical studies, Rams and
Keyes (36) and McCulloch et al. (37), showed that
systemic intake of tetracyclines statistically signifi-
cantly reduced probing pocket depth. The risk of the
occurrence of periodontal destruction after 7 months
was decreased by 43%, and destruction was not
stopped in more than one third of the patients. Some
authors described the reappearance of the disease
after systemic tetracycline therapy (38, 39). Possi-
ble cause of further disease progression are microor-
ganisms inadequately suppressed by tetracycline,
such as A. actinomycetemcomitans (40). Tetracycline
therapy could lead to superinfection with enteric bac-
teria, staphylococci or with Candida albicans (41-43).
It seems that the older studies showed benefi-
cial effect against A. actinomycetemcomitans, while
newer studies do not support this. This can partly be
explained by the higher resistance to these antibi-
otics. Besides this, positive effects were observed in
studies conducted in North america, where different
A. actinomycetemcomitans serotypes are present
with different virulence factors, than in Europe. We
did not find studies in the literature by European
authors showing beneficial effect of tetracyclines
against A. actinomycetemcomitans.
Concerning the choice of tetracyclines, the advan-
tages of doxycycline are one daily dosage, rare gas-
trointestinal adverse effects, as well as normal cal-
cium absorption. Especially interesting is the usage
of low-dosage doxycycline (20-30 mg) during 6-9
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months. Clinical attachment gain has been proved,
without resistance occurrence or changes in normal
periodontal microflora (44). Besides the antimicro-
bial effect, doxycycline inhibits collagenase and
other matrix metalloproteinases, enzymes respon-
sible for collagen degradation during periodontal
infection, so its efficacy is partly due to this mech-
anism (45).
Minocycline, as an adjunct to mechanical thera-
py failed to eliminate A. actinomycetemcomitans in
all patients, and the disease reoccurred in 25% of
the test subjects, despite regular check-ups every 3
months (46).
It seems that the effect of tetracyclines is opti-
mal in patients with ‘refractory’ chronic periodon-
titis, while it is not the best choice for treatment of
localised aggressive periodontitis, due to the weak
effect on A. actinomycetemcomitans the antibiotics
from this group have.
Metronidazole
Metronidazole is a synthetic nitroimidazole. Its
action is bactericidal, acting on anaerobic bacteria,
including gram-negative rods and spirochetes, through
DNA synthesis blocking. Due to the susceptibility
of the spirochetes, it is effective in cases of necrotis-
ing periodontal diseases. It seems relatively ineffec-
tive in the suppression of A. actinomycetemcomi-
tans. Periodontal abscesses can be successfuly treat-
ed with metronidazole, while for aggressive peri-
odontitis treatment its antimicrobial spectrum is not
wide enough (47).
Penicillins
Penicillins inhibit bacterial cell-wall synthesis,
and the antimicrobial spectrum of natural penicillins
is narrow. Amoxicillin is a semi-synthetic penicillin
with broadened antimicrobial spectrum, and is used
in periodontology because it is effective against
some subgingival bacterial species such as P. micros
and A. actinomycetemcomitans as well. It can be used
in cases of acute infections, although it is most com-
monly used in combination with metronidazole.
Amoxicillin in combination with clavulonic acid is
indicated in the presence of oral bacteria capable
of producing β-lactamase (48).
Ciprofloxacin
A member of the fluorquinolones, it is used in the
therapy of urinary infections. Ciprofloxacin is also
effective in the treatment of periodontal superinfec-
tions caused by enteric bacteria, pseudomonas or
staphylococci. Clinical isolates of A. actinomyce-
temcomitans are highly sensitive to ciprofloxacin
(49). Another positive aspect is its inactivity towards
streptococci, whose presence in the subgingival area
is associated with periodontal health. Heightened
streptococcal counts can postpone recolonisation of
the pathogenic bacterial species (50).
Azithromycin
Azithromycin is an antibiotic from the macrolide
group, it exerts bacteriostatic activity by blocking
of bacterial proteins synthesis. The spectrum is broad
and covers gram-negative bacteria, including enteric
bacteria. Assessment of availability in periodontal
tissues showed extremely high values in periodon-
tal tissues, crevicular fluid and saliva. Periodontal-
ly inflamed tissues exhibit concentrations signifi-
cantly higher than healthy periodontal tissues, which
is a very convenient characteristic of this antibiotic
(51). Data from clinical investigations support the
use of azithromycin in the treatment of advanced
chronic, or aggressive periodontitis (52).
Clindamycin
Clindamycin is a pyranoside antibiotic similar to
macrolides, with a broad antimicrobial spectrum.
Efficacy of clindamycin has been tested in several
clinical studies (53, 54). This drug has stopped attach-
ment loss in a high number of patients and increased
the number of sites with the attachment gain, even
in patients who had already undertaken unsuccess-
ful antibiotic therapy. Resistance to clindamycin of
certain A. actinomycetemcomitans and P. gingivalis
serotypes was described (55). Because of the pos-
sibility of dangerous side-effects, as well as the occur-
rence of resistance of certain subgingival microor-
ganisms to this medicaton, it is not the first-choice
antibiotic used in the treatment of periodontal dis-
eases.
It can be concluded that antibiotic monothera-
py, with one medication as an adjunct to the mechan-
ical therapy, has a favourable influence on the com-
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position of bacterial microflora and reduction in the
number of active periodontal pockets. Clinical im-
provement is a result of the total bacterial load sup-
pression, and the changes in the composition of the
subginigival bacterial microflora. Due to the complex
composition of the subgingival bacterial microflo-
ra, such a form of antibiotic therapy is often ineffec-
tive in eliminating exogenous bacterial pathogens.
Combined and serial antibiotic therapy
Subgingival microflora in periodontal diseases
includes different pathogenic bacteria possessing
differential sensitivity to antimicrobials, so the use
of two or more antibiotics presents a useful option
in the treatment of these diseases. The advantages
of combined antibiotic therapy are broadened spec-
trum of antimicrobial activity, occurence od syner-
gistic activity (Table 3) (56) and prevention of bac-
terial resistance development. Disadvantages of such
a treatment are elevated incidence of adverse effects.
Metronidazole in combination with amoxicillin
or ciprofloxacin has been successfuly used in the
treatment of advanced periodontitis, especially infec-
tions with A. actinomycetemcomitans (9, 39, 57, 58).
Metronidazole and amoxicillin in vitro act synergis-
tically on A. actinomycetemcomitans. Combination
of metronidazole with amoxicillin or amoxicillin and
clavulonic acid can eliminate A. actinomyctemco-
mitans and other periodontal pathogens from the
periodontal pockets for at least two years (57, 59).
Metronidazole and ciprofloxacin can be effective in
mixed periodontal infections, such as the presence
of anaerobes, A. actinomycetemcomitans, enteric bac-
teria and pseudomonades (58, 59). As this combina-
tion is ineffective against most gram-positive, fac-
ultative anaerobic bacteria, it can facilitate strepto-
coccal colonisation of the pockets which have no
periodontally pathogenic potential (60).
Serial use of antibiotics is indicated for a combi-
nation of antibiotics, in which one has bactericidal
and the other bacteriostatic activity. Combined admin-
istration would lead to antagonistic effects and ther-
apeutical failure. This form of systemic antimicro-
bial therapy should be used in especially severe cases
of recurrent or refractory periodontitis, where attach-
ment loss was not arrested despite careful initial ther-
apy, or in cases of disease reactivation during the
supportive phase of therapy, occurring despite good
oral hygiene and repeated mechanical subgingival
instrumentation. One of the combinations effective
in the prevention of recurrent periodontitis in high-
risk individuals is doxycycline and metronidazole
(61).
Systemic antimicrobial therapy in periodontal
practice
The main candidates for antibiotic therapy are
periodontal patients, in which conventional mechan-
ical therapy does not arrest further disease progres-
sion. The use of antibiotics is also indicated in patients
with localised aggressive periodontitis or other forms
of early-onset disease, as well as in patients with sys-
temic disease influencing the periodontitis. In patients
with acute or recurrent periodontal infections, like
periodontal abscesses, acute necrotizing gingivitis
or periodontitis (62) or periimplantitis (63), systemic
medication of antibiotics can lead to clinical improve-
ment. Patients with stable periodontitis can profit
from antimicrobial therapy minimally or for a short
period.
Microbiological analysis should be performed
after conventional mechanical therapy has been fin-
ished, in order to assess the need for antibiotic ther-
apy. It should include antimicrobial susceptibility
testing on specific antimicrobials. The microbial test-
ing should be repeated 1-3 months after the antibi-
otic administration, not only to check if elimination
or marked suppression of the pathogens occurred,
but also to monitor for possible superinfections (23,
64, 65).
Microbial sampling of individual or several com-
bined active pockets is conducted. The sample com-
bined from more pockets gives a better insight in the
spectrum of periodontal pathogens that need to be
acted upon through antimicrobial therapy. Repre-
sentative subgingival sample is obtained by com-
bining samples from the deepest pocket bleeding
or showing suppuration, from each quadrant (66). The
samples can be taken by means of sterile curettes
or paper points, and the samples should immediately
be put into the reduced transport media (67).
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Conclusion
The value of systemic antibiotic use in arresting
disease progression has been investigated in numer-
ous studies. It was shown that it can improve the
treatment outcome, as an adjunct to therapy. Seri-
ous adverse effects such as the development of antibi-
otic resistance and growth of opportunistic microor-
ganisms do not support the concept of routine use
of antibiotics in the treatment of chronic, adult forms
of the disease. Systemic antimicrobial therapy is
indicated in cases of disease where the periodontal
destruction continued, despite thoroughly performed
mechanical therapy. In patients from high-risk groups,
such as aggressive forms of periodontitis or peri-
odontitis as a manifestation of systemic disease, the
use of antibiotics is indicated as an adjunct to scal-
ing and root planing. Antibiotics are never indicat-
ed in the treatment of chronic gingivitis.
